Vaginal Cuff Brachytherapy Fractionation Study

Description

The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.

Conditions

Endometrial Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.

A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer

Vaginal Cuff Brachytherapy Fractionation Study

Condition
Endometrial Cancer
Intervention / Treatment

-

Contacts and Locations

Baltimore

University of Maryland Medical Center (UMMC), Baltimore, Maryland, United States, 21201

Syracuse

SUNY Upstate Medical University, Syracuse, New York, United States, 13210

Charlottesville

University of Virginia, Charlottesville, Virginia, United States, 22903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator.
  • * Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection.
  • * Subject must have FIGO Stage I-II (grade 1-3) pathologically proven (histologic) endometrioid cancer, including all subtypes. Serous, clear cell, and carcinosarcoma histologic pathologies are allowed.
  • * Subjects must have no measurable disease after surgery.
  • * ECOG Performance Status of 0-2
  • * Age ≥ 18 years
  • * Subject must have a life expectancy ≥ 12 months
  • * Disease of more advanced stage (FIGO stage III-IV) or disease for which adjuvant external beam radiation therapy or chemotherapy is indicated
  • * Patients with a history of prior pelvic radiation therapy or if additional pelvic radiation therapy is planned
  • * Subjects who have not recovered from side effects of agents administered more than 4 weeks prior to the on-study date
  • * Subjects that require \> 14 weeks between surgery and initiation of radiation therapy on study unless the subject is receiving chemotherapy. Subjects receiving chemotherapy may have radiation therapy initiated within 6 months after surgery.
  • * Subjects who are receiving any investigational agents or have had any investigational agent within the 30 days prior to the on-study date
  • * Subject is unable or unwilling to participate in a study-related procedure
  • * Pregnant and breastfeeding women are excluded from this study
  • * Subject is a prisoner
  • * A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy.
  • * Subjects with a history of evidence upon physical examination of central nervous system disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (stroke), transient ischemic attack, or subarachnoid hemorrhage within six months of study entry

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kara Romano, MD,

Kara Romano, MD, PRINCIPAL_INVESTIGATOR, University of Virginia

Study Record Dates

2026-01-01